Abstract
As both onychomycosis and HIV/AIDS are frequently encountered, we aimed to make a review of the existent information to this moment, including classification, evaluation and treatment. The new description of dermatophytes will surely originate changes in the classification and probably in the therapeutic approach. Also, we must be watchful for the modifications that may develop in this pathology with the newer antirretrovirals which are in constant evolution and could modify the patients’ response to dermatophytosis. At this moment, we know that onychomycosis is very common in patients living with HIV. Although they present similar clinical patterns and aetiological agents to the general population, we must focus in the many differences they present to further understand the physiopathology in the HIV setting. We are still searching for the ideal antimycotic and the full understanding of the pathogenesis of the infection in this particular group of patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
